Grit Biotechnology Recognized in '2025 China Top 100 Biopharmaceutical Leaders' for Innovation and Pipeline Excellence

Nov 27, 2025 08:01 CST Updated 08:01

Grit Biotherapeutics

Developer of Immunotherapy Drugs for Solid Tumors

China, Shanghai – Recently, the highly anticipated "2025 China Biopharmaceutical Top 100" list was grandly unveiled at the 2025 Shanghai Biopharmaceutical Investment and Financing Summit. Grail Bio, an innovative biotechnology company, successfully made it to the "2025 China Biopharmaceutical Top 100" (referred to as "Top 100 Leaders") list with its outstanding R&D capabilities and innovative achievements. This honor fully recognizes Grail Bio's remarkable contributions as an industry leader in driving innovation and development in China's biopharmaceutical sector.

"The Top 100 Leaders in China's Biopharmaceutical Industry" selection aims to identify and honor biopharmaceutical companies that excel in technological innovation, commercial application, and future development potential. It is an important benchmark for measuring a company’s industry standing and innovation capability. This award win signifies that Grail Bio's comprehensive strength and development prospects have gained high recognition from an authoritative industry platform.

Since its establishment, Gravel Biotech has been committed to developing groundbreaking innovative therapies with global impact to address unmet clinical needs. Standing out among many outstanding companies this time not only reflects the company's strengths in core technology platform construction, pipeline layout, operation management, and team execution, but also demonstrates its tremendous future growth potential.

Gravel Biotech's R&D Pipeline Layout:

1. Autologous TIL Pipeline:

(1) GT101 Injection: The first autologous Tumor Infiltrating Lymphocyte (TIL) product in China to be approved for clinical trials, currently in a pivotal clinical stage. Independently developed by the company for second-line treatment of cervical cancer, it is expected to become the first commercialized TIL therapy in China.

2. Gene-Edited Next-Generation TIL Pipeline:

(1) GT201 Injection: The world’s first membrane-bound IL-15 complex engineered TIL drug, which enhances T-cell persistence and tumor-killing ability through genetic engineering. Clinical trials have been conducted simultaneously in China and the United States, showing excellent efficacy across multiple tumor types.

(2) GT307: An iteratively innovative dual-gene knockout edited TIL therapy. GT307 demonstrates significantly enhanced anti-tumor activity by knocking out two novel key immune regulatory genes, resisting T-cell exhaustion and multiple immunosuppressive mechanisms within the tumor microenvironment, while reducing TIL dependency on IL-2 support. Leveraging its self-developed high-throughput CRISPR screening platform ImmuT Finder®, Grail Bio discovered and validated a series of key immune regulatory targets influencing the mechanism of TIL action. Preliminary clinical data for GT307 has shown good safety, with patients having "cold tumors" potentially benefiting from this drug.

3. Neoantigen tumor vaccine and off-the-shelf cell therapy product pipeline:

(1) GT601: An mRNA vaccine targeting neoantigens in tumors. This project utilizes Grail Bio's self-developed and functionally validated high-throughput sequencing combined with AI algorithms to achieve efficient prediction and identification of neoantigens, with a prediction accuracy 10 times higher than common neoantigen prediction technologies. It also employs a specially optimized APC-LNP delivery system for targeted delivery to antigen-presenting cells. Currently, GT601 is preparing to initiate IIT clinical trials.

(2) GT719: The world's first universal CAR-iNKT cell therapy derived from umbilical cord blood stem cells with clinical data. GT719 is currently in the IIT phase, exploring its efficacy in both hematological malignancies and autoimmune diseases, with preliminary safety and efficacy signals showing promising results.

（3）GT801: The Next Generationin vivo CAR-TProduct.GT801 Adopting new type T Cell-Targeting Lipid Nanoparticles (T-LNP) system, precise delivery of contents including anti-CD19 CARGeneticmRNAToTCells, subsequently produced in the bodyanti-CD19 CAR-TCell. Grit UtilizationCLAMPPatented technology that can quickly and accurately completeTCell-targeting antibodies andLNPQuantitative coupling.GT801No need for clear infusion chemotherapy, excellent safety, currently targetingBClinical Researcher-Initiated Trials for Malignant Tumors and Autoimmune Diseases (IIT) has been successfully launched. The pipeline was2025In the year of the split, MicroTide Bio was established and secured an angel round of financing exceeding RMB 100 million, led by Qiming Venture Partners, a globally leading venture capital firm. The funds will be used for the iterative optimization of the core technology platform, as well as the clinical translation and development of the first candidate product in the field of autoimmune diseases.MicroTao Biotech Completes Angel Financing Round of Over 100 Million Yuan）

About Gravel Bio

Gravel Biotech was founded in2019Year, an innovation-driven biopharmaceutical company in the late clinical stage, is committed to pioneering the next generation of immunotherapies for cancer and autoimmune disease patients worldwide. With deep insights in the field of immunotherapy,, cutting-edge R&D and technology platforms, as well as world-class production capabilities, Grail Bio has built multiple self-developed technology platforms in China and the United States, along with a diversified R&D pipeline containing multiple candidate products to meet extensive unmet clinical needs. The company’s self-developedGT101Injection is the first clinically approved product in China.TILDrug, currently entering the critical Phase II clinical trial. Self-developedGT201The injection is the world's first membrane-boundIL-15ComplexTILProduct, has completed China and the United StatesINDDual filing and approval for entryIPhase clinical. In addition, the company also has highly innovative dual-gene knockout autologousTILTherapy Products Targeting Tumor NeoantigensmRNAVaccine, the world's first universal type derived from stem cell differentiationCAR-iNKTCell therapy products, and the next generationin vivo CAR-TAnd many other products, forming pan-solid tumorsTILA product portfolio of drugs and off-the-shelf cell therapies. Grail Bio is committed to overcoming the key limitations in current cancer and autoimmune disease treatments by driving three fundamental shifts to reshape the immunotherapy landscape: from hematological malignancies to solid tumors; from autologous therapies to off-the-shelf allogeneic therapies; and from ex vivo engineering to in vivo engineering, with the goal of revolutionizing the treatment paradigm through breakthrough R&D. Ultimately, this fulfills the company’s mission to provide patients worldwide with highly effective, affordable, and accessible treatment options.